+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models

Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models

International Journal of Cancer 132(7): 1592-1601

To enhance the oncolytic activity of herpes simplex viruses (HSVs) control of immune-suppression and immune-resistance by cancer cells is important. Myeloid-derived suppressor cells (MDSCs), which interfere with tumor-suppressive environments, are inhibited by gemcitabine (GEM) treatment. We investigated the oncolytic activity and systemic antitumor immunity induced by oncolytic HSVs in combination with GEM treatment. A mouse model with subcutaneous tumors on both sides of the lateral flanks was used. A highly attenuated HSV type 1, strain HF10, was inoculated into one side of each tumor three times following intraperitoneal injection of GEM. Histopathological changes and IFN-γ secretion of the tumor and leukocytes in the spleen were analyzed. These treatments were repeated to enhance oncolytic activity. HF10 inoculation reduced tumor growth only on the HF10-treated side. HF10 inoculation following GEM treatment resulted in greater reduction of tumor growth on the HF10-treated tumor; furthermore, reduction of tumors on the contralateral untreated side was also observed. Necrosis of the tumor was observed in areas where HSV-infected cells were detected. F4/80(+) macrophages around the tumor were eliminated, and CD4(+) T and CD8(+) T cells increased in the spleen. A single injection of GEM decreased CD11b(+) /Gr-1(+) MDSCs while retaining CD4(+) T cells and CD8(+) T cells. Repetition of this treatment regimen resulted in even greater reduction of tumor growth on both sides and complete rejection in some of the mice. Intratumoral injection of oncolytic HSVs following GEM injection reduced MDSCs. Repeated treatment with oncolytic HSVs following GEM resulted in enhanced oncolytic activity.

(PDF emailed within 0-6 h: $19.90)

Accession: 052982164

Download citation: RISBibTeXText

PMID: 22949155

DOI: 10.1002/ijc.27823

Related references

Enhanced antitumoral activitiy of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. 2012

Dual-modality imaging demonstrates the enhanced antitumoral effect of herpes simplex virus-thymidine kinase/ganciclovir plus gemcitabine combination therapy on cholangiocarcinoma. Experimental and Therapeutic Medicine 12(1): 183-189, 2016

ICP345 deleted Herpes Simplex Virus 1 with enhanced oncolytic and anti-tumor potential Development of novel replicating vectors for tumor therapy. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1097, March, 2002

Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47 Delta. Cancer Gene Therapy 14(5): 460-467, 2007

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proceedings of the National Academy of Sciences of the United States of America 98(11): 6396-6401, 2001

Tumor efficacy of an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC). Journal of Clinical Oncology 26(15_suppl): 15014-15014, 2016

Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Research 66(9): 4835-4842, 2006

A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. Plos One 9(3): E93103-E93103, 2015

Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication. International Journal of Cancer 129(6): 1503-1510, 2011

Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Research 58(24): 5731-5737, 1998

Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clinical Cancer Research 12(22): 6791-6799, 2006

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. Journal of Ovarian Research 9(1): 70-70, 2016

Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Human Gene Therapy 10(17): 2869-2878, 1999

Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models. Neuro-Oncology 14(3): 288-301, 2012